Amneal Dreams Of Building On Biosimilars To Compete With Other Players
As Generics Segment Revenues Increased By 9.3% To $427m In Q3
Amneal knows what it wants and is determined to get it. With more and more complex products being added to its portfolio, the firm marks another “terrific” quarterly performance.
